All In MedTech

Device Trial Radar · NCT07403058

Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects With Reduced Ejection Fraction

Endovascular Ablation Of The Right Greater Splanchnic Nerve In Subjects Having Heart Failure With Reduced Ejection Fraction: Randomized Controlled Feasibility Trial

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Jun 12, 2026

Primary completion

Mar 1, 2028

Study completion Sep 1, 2028

Sponsor

Lead sponsor
Axon Therapies, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Feb 11, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a small, early-stage clinical trial designed to test whether a new catheter-based procedure is safe and may help people with heart failure with reduced ejection fraction (HFrEF). The procedure uses the Satera Ablation System to treat the right greater splanchnic nerve, which may play a role in heart failure symptoms. The study also aims to identify which types of patients might benefit most from this treatment in the future. Up to 50 patients aged 40 or older with HFrEF will take part at as many as 10 hospitals worldwide. The study is prospective, meaning patients are followed forward in time, and it is randomized, double-blinded, and sham-controlled. Patients are randomly assigned in a 2:1 ratio to either receive the actual nerve ablation treatment or a sham (placebo) procedure. Randomization happens during the procedure, after anesthesia or sedation, to reduce the risk of revealing which treatment the patient receives. Neither the patient nor their heart failure doctor will know whether the patient received the real treatment or the sham. However, the doctor performing the procedure and certain study staff will know, mainly for safety and operational reasons. The sham procedure is designed to mimic the real procedure as closely as possible without performing the nerve ablation. It involves placing a small needle in the groin or neck and accessing the vein, but no treatment catheter is inserted. The sham procedure takes about the same amount of time as the real treatment (around 45 minutes) to help account for any placebo effect. Overall, this study is focused on evaluating safety and early signs of benefit rather than proving long-term effectiveness.

Conditions

  • Heart Failure With Reduced Ejection Fraction (HFrEF)

Interventions

  • Right Greater Splanchnic Nerve (GSN) ablationDevice

    Subjects receive catheter-based unilateral ablation of the right greater splanchnic nerve.

  • Sham ControlProcedure

    Simulated procedure designed to mimic the treatment experience without delivering nerve ablation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Device or procedure related serious adverse eventsTime frame: Treatment through the 1 month
  2. NT-proBNP (6 months)Time frame: Baseline through the 6 months

Locations

9 sites in 5 countries. Site status is shown where the registry gives one.

  • Motol and Homolka University Hospital

    Prague, Czechia · Recruiting

  • Heart and Vascular Clinic

    Tbilisi, Georgia · Recruiting

  • Tbilisi Heart Center

    Tbilisi, Georgia · Recruiting

6 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.